van der Meijs, Nadia L.Travecedo, Maria AlejandraMarcelo, Filipavan Vliet, Sandra J.2025-03-132025-03-1320241472-8222PURE: 106848318PURE UUID: 77636323-4f80-456b-919f-d329f426fc2fScopus: 85197467261PubMed: 38946482http://hdl.handle.net/10362/180582Publisher Copyright: © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.Introduction: CLEC10A is a C-type lectin receptor that specifically marks the conventional dendritic cell subsets two and three (cDC2 and DC3). It has a unique recognition profile of glycan antigens, with terminal N-Acetylgalactosamine residues that are frequently present in the tumor microenvironment. Even though CLEC10A expression allows for precise targeting of cDC2 and DC3 for the treatment of cancer, CLEC10A signaling has also been associated with anti-inflammatory responses that would promote tumor growth. Areas covered: Here, we review the potential benefits and drawbacks of CLEC10A engagement in the tumor microenvironment. We discuss the CLEC10A-mediated effects in different cell types and incorporate the pleiotropic effects of IL-10, the main anti-inflammatory response upon CLEC10A binding. Expert opinion: To translate this to a successful CLEC10A-mediated immunotherapy with limited tumor-promoting capacities, finding the right ligand presentation and adjuvant combination will be key.125007386engC-type lectinCLEC10ADendritic cellsglycobiologyMacrophage galactose-type lectintumor microenvironmentMolecular MedicinePharmacologyDrug DiscoveryClinical BiochemistrySDG 3 - Good Health and Well-beingreview10.1080/14728222.2024.2374743https://www.scopus.com/pages/publications/85197467261